Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
HUTCHMED (China) ( (HK:0013) ) has provided an update.
HUTCHMED (China) Limited has announced that Dr. Weiguo Su, the company’s Chief Executive Officer, will take a leave of absence due to health reasons. In his absence, Mr. Johnny Cheng, currently the Chief Financial Officer, will assume the role of Acting Chief Executive Officer. Mr. Cheng will manage the company’s day-to-day operations while Dr. Su remains as Chief Scientific Officer, supported by the scientific team to continue the company’s drug research and discovery pipeline. The Board has expressed confidence that all research, development, and commercial initiatives will remain on track during this interim period.
The most recent analyst rating on (HK:0013) stock is a Hold with a HK$28.00 price target. To see the full list of analyst forecasts on HUTCHMED (China) stock, see the HK:0013 Stock Forecast page.
More about HUTCHMED (China)
HUTCHMED (China) Limited is an innovative, commercial-stage biopharmaceutical company focused on the discovery, global development, and commercialization of targeted therapies and immunotherapies for cancer and immunological diseases. The company has successfully brought drug candidates from in-house discovery to patients worldwide, with its first three medicines marketed in China and the first also approved in the US, Europe, and Japan.
YTD Price Performance: 12.64%
Average Trading Volume: 10,885,678
Technical Sentiment Signal: Hold
Current Market Cap: HK$22.15B
Learn more about 0013 stock on TipRanks’ Stock Analysis page.